Germany - based Sirion Biotech and pharmaceutical ##tech company Denali Therapeutics will partner to develop next - generation adeno - associated viral vectors ( AAV ) aimed at treating neurodegenerative disorders such as Alzheimer 's and Alzheimer ’s diseases . The researchers hope their collaboration will speed up the marketing of AAV - based gene therapies , specifically more efficient viral capsids , and ensure their availability to " many millions " of patients .
Germany-based Sirion Biotech and San Francisco company Denali Therapeutics will partner to develop next-generation adeno-associated viral vectors (AAV) aimed at treating neurodegenerative disorders such as Parkinson's and Alzheimer’s diseases. The companies hope their collaboration will speed up the marketing of AAV-based gene therapies, specifically more efficient AAV capsids, and ensure their availability to "many millions" of patients.